Hormonal approaches to male contraception.
OBJECTIVE
Condoms and vasectomy are male-controlled family planning methods but suffer from limitations in compliance (condoms) and limited reversibility (vasectomy); thus many couples desire other options. Hormonal male contraceptive methods have undergone extensive clinical trials in healthy men and shown to be efficacious, reversible and appear to be well tolerated.


RESULTS
The success rate of male hormonal contraception using injectable testosterone alone is high and comparable to methods for women. Addition of progestins to androgens improved the rate of suppression of spermatogenesis. Supported by government or nongovernment organizations, current studies aim to find the best combination of testosterone and progestins for effective spermatogenesis suppression and to explore other delivery methods for these hormones. Translation of these advances to widespread use in the developed world will need the manufacturing and marketing skills of the pharmaceutical industry. Availability of male contraceptives to the developing world may require commitments of governmental and nongovernmental agencies. In a time when imbalance of basic resources and population needs are obvious, this may prove to be a very wise investment.


CONCLUSIONS
Male hormonal contraception is efficacious, reversible and well tolerated for the target population of younger men in stable relationships. Suppression of spermatogenesis is achieved with a combination of an androgen and a progestin. Partnership with industry will accelerate the marketing of a male hormonal contraceptive. Research is ongoing on selective androgen and progesterone receptor modulators that suppress spermatogenesis, minimize potential adverse events while retaining the androgenic and gonadotropin suppressive actions.
Wang
Christina
C
Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California 90509, USA. wang@labiomed.org
Swerdloff
Ronald S
RS
D000728:Androgens / Q000494:pharmacology*; D003267:Contraception / Q000379:methods / Q000639:trends*; D003272:Contraceptive Agents, Male / Q000494:pharmacology; D006801:Humans; D008297:Male; D010358:Patient Participation; D013091:Spermatogenesis / Q000187:drug effects*; D016896:Treatment Outcome
D000728:Androgens; D003272:Contraceptive Agents, Male
J Clin Endocrinol Metab. 2004 Jun;89(6):2936-41
15181080
J Clin Endocrinol Metab. 2003 Feb;88(2):562-8
12574181
J Clin Endocrinol Metab. 2009 Jul;94(7):2313-20
19366848
Fertil Steril. 1977 Dec;28(12):1320-8
590541
Am J Obstet Gynecol. 2004 Apr;190(4 Suppl):S60-8
15105800
Contraception. 1978 Dec;18(6):607-14
219988
J Clin Endocrinol Metab. 1998 Oct;83(10):3527-33
9768659
Lancet. 1992 Apr 11;339(8798):887-9
1348296
J Clin Endocrinol Metab. 1996 Feb;81(2):757-62
8636300
JAMA. 2006 Nov 15;296(19):2351-61
17105798
Lancet. 2006 Apr 29;367(9520):1412-20
16650651
J Clin Endocrinol Metab. 1987 May;64(5):931-6
3104388
Hum Reprod. 2000 Mar;15(3):637-45
10686211
Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):735-41
8672990
J Clin Endocrinol Metab. 2002 Feb;87(2):530-9
11836281
J Clin Endocrinol Metab. 1979 Oct;49(4):520-6
479345
J Clin Endocrinol Metab. 1998 Mar;83(3):870-6
9506742
Lancet. 1990 Oct 20;336(8721):955-9
1977002
Endocrinology. 2006 Jun;147(6):3016-26
16497801
J Clin Endocrinol Metab. 2008 Jul;93(7):2572-80
18413423
J Clin Endocrinol Metab. 2009 Jun;94(6):1910-5
19293262
J Clin Endocrinol Metab. 1991 Jun;72(6):1242-8
1827450
Fertil Steril. 1985 Jul;44(1):96-101
3924670
J Clin Endocrinol Metab. 1998 Jun;83(6):2104-9
9626146
J Clin Endocrinol Metab. 1999 Jan;84(1):112-22
9920070
Hum Reprod. 2000 Mar;15(3):646-9
10686212
J Clin Endocrinol Metab. 1996 Nov;81(11):4113-21
8923869
Contraception. 1977 Sep;16(3):261-8
913115
Hum Reprod. 2005 Feb;20(2):549-56
15608042
J Clin Endocrinol Metab. 2003 Nov;88(11):5232-9
14602755
J Clin Endocrinol Metab. 1998 Jan;83(1):152-6
9435433
Endocrinology. 2009 Jan;150(1):385-95
18772237
Fertil Steril. 1996 Apr;65(4):821-9
8654646
Stud Fam Plann. 1982 Nov;13(11):328-42
6965184
J Clin Endocrinol Metab. 2002 Aug;87(8):3562-72
12161475
J Clin Endocrinol Metab. 1993 Aug;77(2):427-32
8345047
Steroids. 2003 Nov;68(10-13):965-72
14667989
Mol Cell Endocrinol. 2001 Sep;182(2):175-9
11514052
Stud Fam Plann. 1978 Aug;9(8):229-31
568835
J Androl. 2003 Jul-Aug;24(4):466-83
12826683
J Clin Endocrinol Metab. 2006 Feb;91(2):460-70
16278260
J Androl. 2006 Jul-Aug;27(4):483-90
16598028
J Clin Endocrinol Metab. 1989 Feb;68(2):446-54
2537334
J Clin Endocrinol Metab. 2008 May;93(5):1774-83
18303073
J Clin Endocrinol Metab. 2003 Oct;88(10):4659-67
14557437
J Med Chem. 2009 Jun 25;52(12):3597-617
19432422
J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):214-22
18555683
Nucl Recept Signal. 2008;6:e010
19079612
Hum Reprod. 1999 Sep;14(9):2200-6
10469681
J Clin Endocrinol Metab. 1985 May;60(5):998-1003
3920237